Roche Inks $1.45 Billion Deal with China’s Hansoh Pharma for Promising Colorectal Cancer ADC
In a strategic move to bolster its oncology portfolio, Roche has secured global rights to an investigational antibody-drug conjugate (ADC) from Chinese biotech firm Hansoh Pharma, targeting colorectal cancer and other solid tumors. The deal, announced this week, includes an upfront payment of $80 million to Hansoh’s subsidiaries, Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical, with potential milestone payments reaching up to $1.45 billion based on development and commercialization successes. The asset in question, HS-20110, is an early-stage ADC designed to selectively target the CDH17 protein, which is overexpressed in colorectal cancers and certain other gastrointestinal malignancies. CDH17, a cadherin family member involved in cell adhesion, has emerged as a promising therapeutic target due to its limited expression in healthy tissues, potentially reducing off-target toxicities common in earlier ADC generations. HS-20110 leverages this specificity to deliver cytotoxic payloads directly to…


